What is the main purpose of this 10-Q filing for Bristol Myers Squibb?

The main purpose of this 10-Q filing is to provide investors and the public with a quarterly update on Bristol Myers Squibb's financial performance, operational activities, and any significant events that occurred during the period ending March 30, 1999. It is a mandatory filing with the U.S. Securities and Exchange Commission (SEC).

What key financial information can I expect to find in the full 10-Q report?

The full 10-Q report typically contains unaudited financial statements (income statement, balance sheet, cash flow statement), a Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A) providing context for the financial results, details on any material legal proceedings, and information on risk factors. Specifics on revenue from key products, research and development expenses, and sales trends are crucial for investors.

Where can I find the complete 10-Q filing for BMY from May 1999?

The complete 10-Q filing can be accessed through the U.S. Securities and Exchange Commission's EDGAR database. Investors can search for the company (BMY) and the specific filing date (May 13, 1999) to retrieve the full document, which will contain detailed financial data and narrative analysis beyond this directory excerpt.

BRISTOL MYERS SQUIBB CO 10-Q Quarterly Report Q1 FY1999

Summary

Bristol Myers Squibb (BMY) filed its Form 10-Q for the period ending March 30, 1999. While the provided filing excerpt focuses on the SEC's EDGAR system directory and metadata, it indicates the company is actively reporting its financial performance. Investors would typically look for details on revenue, profitability, product pipeline developments, and any significant strategic changes within the full 10-Q document. Without the financial statements and management discussion and analysis (MD&A), a deep dive into BMY's operational and financial health for this specific quarter is not possible from this snippet. However, the filing itself signifies ongoing financial disclosure. Investors should consult the complete 10-Q filing to understand BMY's performance relative to prior periods and market expectations, including any commentary on key drug sales, research and development investments, and overall financial outlook. The presence of this filing suggests standard corporate governance and transparency practices by Bristol Myers Squibb.

Key Highlights

1Bristol Myers Squibb (BMY) filed its Quarterly Report (10-Q) for the period ending March 30, 1999.
2The filing was made with the SEC on May 13, 1999.
3This report pertains to the company's financial and operational performance during the first quarter of 1999.
4The provided content is an excerpt from the SEC's EDGAR filing system, listing directory information.
5Investors would typically seek detailed financial statements, revenue breakdowns, and management discussion within the full 10-Q to assess performance.
6The filing indicates BMY's adherence to regular financial reporting requirements.

BRISTOL MYERS SQUIBB CO Quarterly Report for Q1 Ended Mar 31, 1999

Summary

Key Highlights

Frequently Asked Questions